Top 75 Immunotherapy startups
Updated: December 01, 2020 |
Immunotherapy
is a type of cancer treatment designed to boost the body's natural
defenses to fight the cancer. It uses materials either made by the body
or in a laboratory to improve, target, or restore immune system
function.
...
1
Country: USA | Funding: $1.7B
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
2
Country: Germany | Funding: $741.9M
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
3
Country: Switzerland | Funding: $526M
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers. ADC Therapeutics employs monoclonal antibodies specific to particular tumor antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine (PBD) -based warheads to selectively kill cancer cells.
4
Country: USA | Funding: $300 m
Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.
Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.
5
Country: USA | Funding: $226.7M
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
6
Country: USA | Funding: $222.9M
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Atreca develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
7
Country: China | Funding: $217.8M
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
Rakuten Aspyrian is developing tumor-targeted precision therapies based on its proprietary platform Photoimmunotherapy.
8
Country: USA | Funding: $209.6M
We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.
We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases.
9
Country: USA | Funding: $200M
D3 Bio identifies areas of unmet need in immunology and oncology and use existing clinical data to find precision medicine targets and delivery methods with the potential to improve outcomes.
D3 Bio identifies areas of unmet need in immunology and oncology and use existing clinical data to find precision medicine targets and delivery methods with the potential to improve outcomes.
10
Country: UK | Funding: $191.8M
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
Kuur Therapeutics is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.
Ad
Advertise your startup
11
Country: China | Funding: $190M
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
JW is focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.
12
Country: USA | Funding: $187.2M
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
13
Country: UK | Funding: $181.7M
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
Autolus utilises advanced cell programming CAR-T and manufacturing technologies and we have established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.
14
Country: USA | Funding: $178.3M
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
Using our proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, we are discovering and developing new cellular immunotherapies for cancer. The company doesn’t intend to make its own antibodies in-house, but rather align with various companies that want to enhance their experimental antibody drugs.
15
Country: USA | Funding: $177.5M
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy.
16
Country: USA | Funding: $166M
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
17
Country: USA | Funding: $165.2M
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases.
18
Country: USA | Funding: $164M
Shattuck develops cancer immunotherapy, with immune checkpoint blockade, has provided profound benefit for patients with late-stage cancers.
Shattuck develops cancer immunotherapy, with immune checkpoint blockade, has provided profound benefit for patients with late-stage cancers.
19
Country: USA | Funding: $161M
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
20
Country: USA | Funding: $156M
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
21
Country: France | Funding: €17.4M
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer.
22
Country: USA | Funding: $145M
Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.
Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.
23
Country: USA | Funding: $140M
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
24
Country: UK | Funding: £113.2M
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
25
Country: USA | Funding: $135.7M
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve – not just treat, but solve – significant problems in oncology, genetic disease, agriculture, and beyond via its proprietary ARCUS genome editing platform.
Precision BioSciences is a genome editing company dedicated to improving life. Our team seeks to solve – not just treat, but solve – significant problems in oncology, genetic disease, agriculture, and beyond via its proprietary ARCUS genome editing platform.
26
Country: USA | Funding: $132.5M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
27
Country: USA | Funding: $123M
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
28
Country: UK | Funding: $117.9M
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
29
Country: UK | Funding: $116.2M
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
30
Country: USA | Funding: $108.5M
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, we are well positioned in an exciting new era of immuno-oncology.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, we are well positioned in an exciting new era of immuno-oncology.
31
Country: USA | Funding: $103 m
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
32
Country: USA
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
33
Country: Netherlands | Funding: €88M
Lava Therapeutics has developed a proprietary platform focused on developing next generation T cell engaging bispecific antibodies.
Lava Therapeutics has developed a proprietary platform focused on developing next generation T cell engaging bispecific antibodies.
34
Country: Ireland | Funding: $95M
Transforming cancer treatments and the lives of cancer patients by targeting the molecular pathways that drive the most aggressive and resistant forms of cancer.
Transforming cancer treatments and the lives of cancer patients by targeting the molecular pathways that drive the most aggressive and resistant forms of cancer.
35
Country: USA | Funding: $92,5m
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
36
Country: USA | Funding: $85.3M
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Acquired by Gilead Sciences
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. Acquired by Gilead Sciences
37
Country: Belgium | Funding: $78.2M
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
38
Country: France | Funding: €68M
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators.
39
Country: USA | Funding: $73M
Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics.
Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics.
40
Country: UK | Funding: £52.6M
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
41
Country: USA | Funding: $69M
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
BioXcel Therapeutics is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
42
Country: USA | Funding: $67M
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs.
43
Country: USA | Funding: $62.5M
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
44
Country: USA | Funding: $61.8M
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, multiple sclerosis (MS).
45
Country: USA | Funding: $62M
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
46
Country: USA | Funding: $56.9M
CARMA TherapeuticsSM is a biotechnology company founded in 2016 to bring the power of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimeric antigen receptor macrophages (CARMA).
CARMA TherapeuticsSM is a biotechnology company founded in 2016 to bring the power of adoptive cellular immunotherapy to solid tumor patients through a novel platform using chimeric antigen receptor macrophages (CARMA).
47
Country: USA | Funding: $55M
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
48
Country: USA | Funding: $52M
Be Biopharma engineers B-cell therapies. The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene.
Be Biopharma engineers B-cell therapies. The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene.
49
Country: USA
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system.
50
Country: USA | Funding: $50M
Verseau is the Macrophage Company Transforming Immunotherapy
Verseau is the Macrophage Company Transforming Immunotherapy
51
Country: USA | Funding: $47.6 m
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
52
Country: Israel | Funding: $40M
KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.
KAHR Medical develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases.
53
Country: France | Funding: $37.5M
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
54
Country: USA | Funding: $35M
Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer.
Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer.
56
Country: USA | Funding: $32.5M
ImmunoCellular Therapeutics is focused on improving cancer treatment and diagnosis through the development of new immune-based products.
ImmunoCellular Therapeutics is focused on improving cancer treatment and diagnosis through the development of new immune-based products.
57
Country: USA | Funding: $29.4M
SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies.
SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies.
58
Country: USA | Funding: $29M
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies.
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies.
59
Country: China | Funding: $27.5M
Immunochina provides cancer diagnosis and treatment services based on Chimeric Antigen Receptor T-cell immunotherapy.
Immunochina provides cancer diagnosis and treatment services based on Chimeric Antigen Receptor T-cell immunotherapy.
60
Country: USA | Funding: $25M
A discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
A discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
61
Country: Canada | Funding: $24M
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
62
Country: Israel | Funding: $20M
NeoTX Therapeutics is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy.
NeoTX Therapeutics is a specialty biopharmaceutical company, with a focus on research and development in oncology immunotherapy.
63
Country: USA | Funding: $16.5M
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalin proteins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin protein to treat anemia.
64
Country: China | Funding: $16.5M
ONCOLOGIE is an oncology therapeutics company committed to delivering better outcomes for cancer patients through an improved understanding of which patients will benefit from each drug in the pipeline
ONCOLOGIE is an oncology therapeutics company committed to delivering better outcomes for cancer patients through an improved understanding of which patients will benefit from each drug in the pipeline
65
Country: UK | Funding: $16M
Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer.
Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer.
66
Country: USA | Funding: $15M
Neogene Therapeutics provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
Neogene Therapeutics provide cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
67
Country: USA | Funding: $11.8M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
68
Country: USA | Funding: $10.5M
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. These mutations form during the development and progression of cancer.
Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. These mutations form during the development and progression of cancer.
69
Country: USA | Funding: $7M
The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a major barrier to the clinical success of oncolytic viruses. This barrier is the body’s immune system, which is very effective at killing both harmful viruses (like flu) and beneficial viruses (like oncolytic viruses).
The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a major barrier to the clinical success of oncolytic viruses. This barrier is the body’s immune system, which is very effective at killing both harmful viruses (like flu) and beneficial viruses (like oncolytic viruses).
70
Country: USA | Funding: $4.5M
Grid is developing the first human derived targeted immunotherapy for cancer.
Grid is developing the first human derived targeted immunotherapy for cancer.
71
Country: Belgium | Funding: $3.55M
Oncurious focuses on clinical development activities in orphan pediatric oncology treatment with a focus on preclinical research and drug development programs, enabling its clients to receive new approaches for immuno-oncology drugs targeting a broad spectrum of cancers.
Oncurious focuses on clinical development activities in orphan pediatric oncology treatment with a focus on preclinical research and drug development programs, enabling its clients to receive new approaches for immuno-oncology drugs targeting a broad spectrum of cancers.
72
Country: USA | Funding: $150K
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
73
Country: Netherlands
Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells or antigen presenting cell in the field of cellular cancer immunotherapy.
Glycostem is a clinical-stage company, harvesting the power of allogeneic cells like Natural Killer (NK) cells or antigen presenting cell in the field of cellular cancer immunotherapy.
74
Country: Argentina
VIROgene is pioneering the development of life-changing treatments for severe diseases with engineered viruses that harbor therapeutic genes to cure diseases at the molecular level.
VIROgene is pioneering the development of life-changing treatments for severe diseases with engineered viruses that harbor therapeutic genes to cure diseases at the molecular level.
75
Country: USA
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
kernal biologics is mRNA vaccine and therapeutics company. It develops onco-selective mRNA immunotherapy
